NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 52.83%.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 99.99M USD.
Infravalorada
El PE más reciente de la empresa es -25.02, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 33.54M acciones, lo que supone una reducción del 11.02% con respecto al trimestre anterior.
En posesión de Steven Cohen
El inversor estrella Steven Cohen posee 117.23K acciones de este valor.